ABSTRACT
Objective:To observe the clinical effects and adverse reactions of meropenem in the treatment of severe lung infection. Methods:Totally 62 severe bacterial lung infection patients were randomly divided into two groups randomly. The patients in the con-trol group (31 cases ) were treated with cefoperazone / sulbactam 2-8 g in 100 ml 0. 9% sodium chloride injections,ivd,q12h, and the treatment group (31 cases ) was treated with meropenem 1 g in 100 ml 0. 9% sodium chloride injections,ivd,q8h. The treatment course was 14 days. The bacterial clearance rate, dual infection rate, clinical efficacy and adverse drug reactions of the two groups were observed and compared. Results:The bacterial clearance rate in the control group was 85. 2% and that in the treatment group was 92. 85% (P>0. 05). The incidence rate of dual infection in the treatment group (3. 6%) was significant lower than that in the control group (P0. 05). Conclusion:Meropenem is ef-fective in the treatment of severe bacterial lung infection. It can clear bacteria and reduce dual infection effectively, which shows better efficacy than cefoperazone / sulbactam.
ABSTRACT
OBJECTIVE:To evaluate the antibiotic activity of Moxifloxacin (MFX) combined with Cefoperazone/Sulbactam (CPZ/SBT) against clinical common resistant bacteria for clinical reference of rational use of antibacterials.METHODS: The MIC of two antibiotics used alone or in combination on staphylococcus aureus,Klebsiella pneumoniae,Pseudomonas aeruginosas(50 strains,respectively)and Escherichia coli,enterobacter cloacae(20 strains,respectively)were detected respectively by Vitek-32 Model (Full Automated bacterium Detection Device) and the fractional inhibitory concentration(FIC) index was calculated. RESULTS: The combination of two antibiotics significantly reduced MIC on 190 common resistant pathogenic strains and enhanced antibiotic action. Their antibacterial action in vitro was characterized by synergism and additive action. CONCLUSION: The study can present reference for hospital treatment of infection induced by common drug-resistant bacteria.